Digital Self-Management and Health Coaching for Type 2 Diabetes - Impact on Diabetes Clinical and Wellness Indicators

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Digital Self-Management and Health Coaching for Type 2 Diabetes - Impact on Diabetes Clinical and Wellness Indicators

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04057248
• Other study ID #: CP-0010
• Status: Completed
• Phase: N/A
• Start date: July 9, 2018
• Est. completion date: June 1, 2019

Study information

• Verified date: September 2019
• Source: LabStyle Innovations Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Each subject enrolled in the study will be requested to complete an intake questionnaire including diabetes quality of life questions. The subject will use Dario Blood glucose monitoring system and will be contacted by a Certified Diabetes Educator (CDE) two to three times a month as well as have a direct communication using other communication channels such as mail, chat and text messaging (SMS) for lifestyle and diabetes management coaching for a total duration of three months. In the end of study, the subject will complete a diabetes quality of life questionnaire and have a blood test to evaluate its clinical parameters.

Description:

This study is designed to assess the effect of digital self-monitoring platform used with the remote support of a Health coach on clinical outcomes and Diabetes quality of life.

Study design will be an open-label randomized trial of adults with Type 2. Patients are recruited through the Diabetes and Endocrinology Consultants center setting. Upon randomization to the intervention group, study participants will receive three months diabetes health coaching comprising of:

1. Two scheduled phone sessions with a Diabetes health coach a month;

2. Ongoing dual communication with the coach using digital communication channels such as chat, SMS and emails

3. Diabetes education, behavior modification, goal setting and reinforcement. The Dario App will record participant's glucose measurements and additional information captured by the patient such as medication intake, food and physical activity results.

The coach will get access to the patients' App captured information and will intervene ad necessary in the context of the clinical information.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: June 1, 2019
• Est. primary completion date: June 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years and older

Eligibility

Inclusion Criteria:

To be eligible to participate in this study, a subject must meet all the following criteria:

1. Adults 35 years of age or older

2. Diagnosed type 2 Diabetes

3. HbA1C test taken less than 2 months ago and is equal to or above 8.5%

4. Able to read, write and understand English

5. Have supported smartphone (see appendix C for the full smartphone list) with internet package for their service provider

6. The subject is able and agrees to sign the informed consent form

Exclusion Criteria:

1. Adults with impaired cognition

2. Cohabiting with a participant in the study

3. Have an underlying medical condition (such as kidney disease, hemoglobin variants, anemia) that may provide misleading A1C levels

4. Subject is critically ill

5. Subject has an impairment that prevents him/her from following the study procedures

6. Subject is not using medication that may interfere with the blood glucose measurement

7. HCT level which are outside Dario BGMS declared range (20%-60%)

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Device:
• Dario Blood Glucose Monitoring System
Dario Blood Glucose Monitoring System (BGMS) with Dario App and Dario digital platform

Behavioral:
• CDE
Certified Diabetes Educator Sessions

Locations

Country	Name	City	State
United States	Diabetes and Endocrinology Consultants of Pennsylvania, LLC (Decpa LLC)	Feasterville	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
LabStyle Innovations Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HbA1C Value at 3 Months From Subject Start of Study Compared to Baseline	Change of HbA1C taken in blood test 3 month from the subject start of the study.; Data was compared to baseline and reporting the HbA1C change from baseline measurement and 3 months after subject start of the clinical study.; Measurement was conducted by Quest labs.	During 3 Months
Secondary	Cholesterol Value at 3 Months From Subject Start of Study	Change of Cholesterol taken in blood test 3 month from the subject start of the study Data was compared to baseline and reporting the Cholesterol change from baseline measurement and 3 months after subject start of the clinical study.; Measurement was conducted by Quest labs,	During 3 months
Secondary	Weight Value at 3 Months From Subject Start of Study	Change of Weight taken in the clinic at the beginning of the study and 3 month from the subject start of the study Data was compared to baseline and reporting the weight change from baseline measurement and 3 months after subject start of the clinical study.	During 3 months
Secondary	Triglycerides Value at 3 Months From Subject Start of Study	Change of Triglycerides taken in blood test 3 month from the subject start of the study Data was compared to baseline and reporting the Triglycerides change from baseline measurement and 3 months after subject start of the clinical study.; Measurement was conducted by Quest labs,	During 3 months